Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The 5-hydroxytryptamine receptor 3 (5-HT3 receptor) is a member of the serotonin receptor family and is unique among them as a ligand-gated ion channel (as opposed to the other G protein-coupled serotonin receptors). It is predominantly expressed in the central and peripheral nervous system, where it mediates fast excitatory neurotransmission in response to serotonin. The 5-HT3 receptor is involved in the regulation of nausea and vomiting, mood modulation, anxiety, and pain transmission. Antagonists of this receptor, such as mirtazapine and ondansetron, are used to treat conditions like major depressive disorder and chemotherapy-induced nausea and vomiting, respectively. Mirtazapine acts as a noncompetitive antagonist at this receptor, contributing to its antidepressant and anxiolytic effects by altering serotonergic neurotransmission.
Antagonists of the 5-HT3 receptor inhibit serotonin-mediated excitatory neurotransmission; mirtazapine is a noncompetitive antagonist. 5-HT3 antagonists block ion channel opening by serotonin (5-hydroxytryptamine), reducing neural transmission related to emesis and mood.
6 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on 5-hydroxytryptamine receptor 3 (5-HT3 receptor) (5-HT3R).